肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：SPOP突变/CHD-1缺失前列腺癌与阿比特龙敏感性

2018-11-22 MedSci MedSci原创

前列腺癌阿比特龙SPOPCHD-1
关注

CHD1缺失和SPOP突变经常在前列腺癌中共同发生，在去势抵抗性前列腺癌（CRPC）中报道的频率较低。CLIN CANCER RES近期发表了一篇文章，在疾病进展过程中监测CHD1表达情况并评估CHD1 -deleted / SPOP -mutated转移性CRPC（mCRPC）的分子和临床特征。

CHD1缺失和SPOP突变经常在前列腺癌中共同发生，在去势抵抗性前列腺癌（CRPC）中报道的频率较低。CLIN CANCER RES近期发表了一篇文章，在疾病进展过程中监测CHD1表达情况并评估CHD1 -deleted / SPOP -mutated转移性CRPC（mCRPC）的分子和临床特征。

研究共纳入89例患有mCRPC的患者，这些患者未接受过激素治疗且存在去势抗性。通过IHC分析这些患者的CHD1，PTEN和ERG表达。通过靶向的二代测序（NGS）确定SPOP状态。作者还研究了这些生物标志物与诊断后的总体存活率，CRPC的总体生存率，阿比特龙治疗的持续时间，对阿比特龙的治疗反应等之间的相关性。使用Cox回归分析与结果之间的关系。研究结果表明，激素敏感性前列腺癌（HSPC）活检样本中有11例（15％）检测到CHD1蛋白缺失，CRPC活检样本中有13例（17％）检测到CHD1蛋白缺失。在56例匹配的相同患者的HSPC和CRPC活组织中可以检测CHD1表达。56例中有55例HSPC和CRPC中的CHD1蛋白状态存在相关。研究发现了22名患有体细胞SPOP突变的患者，其中6种突变之前未见于前列腺癌。SPOP突变和/或CHD1缺失与阿比特龙更高的治疗反应和阿比特龙用药时间更长相关。

文章最后认为，SPOP突变的mCRPC往往存在CHD1缺失。这些肿瘤患者对阿比特龙治疗高度敏感。

原始出处：

Gunther Boysen, Daniel N. Rodrigues, et al. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. CLIN CANCER RES. November 2018 doi:10.1158/1078-0432.CCR-18-0937

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993132, encodeId=4a9f19931328c, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Tue Feb 05 23:42:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782966, encodeId=3f3d1e82966d3, content=<a href='/topic/show?id=b6b745965d' target=_blank style='color:#2F92EE;'>#CHD-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4596, encryptionId=b6b745965d, topicName=CHD-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 02 01:42:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353756, encodeId=2e25353e562e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 27 07:45:56 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334734, encodeId=faa31334e3475, content=<a href='/topic/show?id=6345459514' target=_blank style='color:#2F92EE;'>#CHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4595, encryptionId=6345459514, topicName=CHD)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/OKNjeqMuGQiclFVAJtO8Yvicr3uMFOHysUY3EYJses2g3YQKBAT7FzaJwAfeVrbPEPnsiaBAicMAJX7icLdcxzMj0kA/132, createdBy=038e2500100, createdName=ms7517674339485982, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388435, encodeId=c14f1388435f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2019-02-05 ms8888626721583891

    #SPOP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1993132, encodeId=4a9f19931328c, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Tue Feb 05 23:42:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782966, encodeId=3f3d1e82966d3, content=<a href='/topic/show?id=b6b745965d' target=_blank style='color:#2F92EE;'>#CHD-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4596, encryptionId=b6b745965d, topicName=CHD-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 02 01:42:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353756, encodeId=2e25353e562e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 27 07:45:56 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334734, encodeId=faa31334e3475, content=<a href='/topic/show?id=6345459514' target=_blank style='color:#2F92EE;'>#CHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4595, encryptionId=6345459514, topicName=CHD)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/OKNjeqMuGQiclFVAJtO8Yvicr3uMFOHysUY3EYJses2g3YQKBAT7FzaJwAfeVrbPEPnsiaBAicMAJX7icLdcxzMj0kA/132, createdBy=038e2500100, createdName=ms7517674339485982, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388435, encodeId=c14f1388435f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2019-11-02 xiaoyeshuang

    #CHD-1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1993132, encodeId=4a9f19931328c, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Tue Feb 05 23:42:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782966, encodeId=3f3d1e82966d3, content=<a href='/topic/show?id=b6b745965d' target=_blank style='color:#2F92EE;'>#CHD-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4596, encryptionId=b6b745965d, topicName=CHD-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 02 01:42:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353756, encodeId=2e25353e562e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 27 07:45:56 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334734, encodeId=faa31334e3475, content=<a href='/topic/show?id=6345459514' target=_blank style='color:#2F92EE;'>#CHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4595, encryptionId=6345459514, topicName=CHD)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/OKNjeqMuGQiclFVAJtO8Yvicr3uMFOHysUY3EYJses2g3YQKBAT7FzaJwAfeVrbPEPnsiaBAicMAJX7icLdcxzMj0kA/132, createdBy=038e2500100, createdName=ms7517674339485982, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388435, encodeId=c14f1388435f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-27 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1993132, encodeId=4a9f19931328c, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Tue Feb 05 23:42:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782966, encodeId=3f3d1e82966d3, content=<a href='/topic/show?id=b6b745965d' target=_blank style='color:#2F92EE;'>#CHD-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4596, encryptionId=b6b745965d, topicName=CHD-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 02 01:42:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353756, encodeId=2e25353e562e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 27 07:45:56 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334734, encodeId=faa31334e3475, content=<a href='/topic/show?id=6345459514' target=_blank style='color:#2F92EE;'>#CHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4595, encryptionId=6345459514, topicName=CHD)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/OKNjeqMuGQiclFVAJtO8Yvicr3uMFOHysUY3EYJses2g3YQKBAT7FzaJwAfeVrbPEPnsiaBAicMAJX7icLdcxzMj0kA/132, createdBy=038e2500100, createdName=ms7517674339485982, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388435, encodeId=c14f1388435f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 ms7517674339485982

    #CHD#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1993132, encodeId=4a9f19931328c, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Tue Feb 05 23:42:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782966, encodeId=3f3d1e82966d3, content=<a href='/topic/show?id=b6b745965d' target=_blank style='color:#2F92EE;'>#CHD-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4596, encryptionId=b6b745965d, topicName=CHD-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 02 01:42:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353756, encodeId=2e25353e562e, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Nov 27 07:45:56 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334734, encodeId=faa31334e3475, content=<a href='/topic/show?id=6345459514' target=_blank style='color:#2F92EE;'>#CHD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4595, encryptionId=6345459514, topicName=CHD)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/OKNjeqMuGQiclFVAJtO8Yvicr3uMFOHysUY3EYJses2g3YQKBAT7FzaJwAfeVrbPEPnsiaBAicMAJX7icLdcxzMj0kA/132, createdBy=038e2500100, createdName=ms7517674339485982, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388435, encodeId=c14f1388435f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Nov 24 09:42:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 ms5236388012055669

    #敏感性#

    0

相关资讯

Urol Int：在低风险前列腺癌患者中，中性粒细胞、血小板和嗜酸性粒细胞/淋巴细胞比例能够预测格林森评分升级

一些生化和临床标记已经用于选择进行积极监控（AS）的患者。然而，其中的一些标记昂贵并且不容易获得。更多的是，目前大约30%进行AS的患者具有疾病恶化现象。因此，开发其他的工具来准确鉴定低风险前列腺癌患者（PCa）是迫切需要的。研究人员回顾性的调查了260名经历根治性前列腺切除术患者的医疗记录，并且符合AS的标准，并利用单变量和多变量分析的方法评估了患者与肿瘤再次分级特性之间的相关性。一个基础的模型

Lancet oncol：活检前进行多参数MRI检查可提高前列腺癌的检出率，但不能取代活检

多参数MRI是否能显着提高前列腺癌的临床检出率，进而避免活检？研究人员在法国的16个中心开展一前瞻性的配对诊断研究，招募18-75岁的前列腺特异性抗体≤20mg/mL的T2c期级以下的前列腺癌患者，且要求患者在第一次前列腺活检前进行过多参数MRI检查，MRI检查和活检的间隔不超过3个月。MRI检查阳性则根据MRI结果进行活检，MRI检查阴性，则仅进行系统活检。主要结点是前列腺癌（csPCa-A）的

PLoS One：青少年痤疮与前列腺癌风险相关么？

之前关于痤疮和前列腺癌风险关系的研究报道了并不一致的结果。最近，有研究人员进行了观察性研究的元分析来概括两者相关性的证据。研究人员在PubMed、Scopus、Web of Science和中国知网(CNKI)数据库中对文献进行了综合的搜索，截止时间到2018年，并利用随机影响模型评估了风险比（ORs）和95%置信区间（CIs），还利用了Q统计和I2指数评估了不同研究的异质性。他们的元分析总共包括

Eur J Cancer Care (Engl)：接受新药物治疗的前列腺癌患者的疲劳、治疗满意度和健康相关生活质量研究

临床研究已经阐释了醋酸阿比特龙+强的松（AAP）和恩杂鲁胺（ENZ）在显著改善转移性去势难治性前列腺癌患（mCRPC）者生存中的作用。然而，考虑到患者现实生活中的经历，尤其是考虑到疲劳、治疗满意度和健康生活质量（HRQoL），相关的研究很有限。最近，有研究人员进行了相关的研究。他们在研究开始对38名患者和12名护理者行了采访，目的消除他们生活经历中的定性数据。之后，研究人员对mCPRC（n=152

N Z Med J：早期前列腺癌低剂量率近距离放射治疗10年结果的前瞻性预估

诊断为早期阶段前列腺癌的新西兰男性需要知道他们的治疗选择将会产生怎样的预期结果。最近，有研究人员就诊断上述期望进行了相关研究。在2001年和2016年之间，951名新西兰男性接受了低剂量率近距离放射治疗（永久性碘125种子植入）。在治疗后跟踪调查期间，他们进行了PSA 检测和泌尿、排便和性副作用评分。研究发现，跟踪调查的平均时间为7.9年（2.0-16.3年）。10年PSA控制在551名低风险前列

J Clin Pharmacol：在前列腺癌患者中，雄激素阻断治疗能够增加心脏衰竭的风险

最近，研究人员在前列腺癌患者中调查了雄激素阻断治疗与心脏衰竭之间的相关性。研究的群体数据来自中国台湾2005年的纵向健康保险数据库。在整个群体研究中，研究人员见顶了1244名前列腺癌患者，他们均接受了雄激素阻断治疗。另外，还包括了1806名前列腺癌患者，他们并没有接受雄激素阻断治疗，且作为比较群体。为了消除潜在的偏差，研究人员还进行了得分匹配的群体研究。研究人员还对每一位前列腺癌患者进行了为期1年